Deal Watch: Seattle Genetics Adds To Antibody-Drug Conjugate Portfolio

Looking to expand beyond Adcetris, Seattle Genetics pays $250m up front for Immunomedics' Phase I/II ADC for triple-negative breast cancer. Elsewhere in the ADC space, Swiss biotech Novimmune and South Korea's LegoChem are teaming up on a research collaboration.